5398S-13: CTSU 9177 DLBCL

CTSU 9177: Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma

Type of Study
Cancer (Oncology) - Lymphoma
Location
Swedish Cancer Institute
Short Description
Purpose: To determine the safety and effectiveness of DA-EPOCH-R in treating Burkitt lymphoma.

Effective 2/26/2014, the C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma treatment arms are permanently closed.  Only the Burkitt Lymphoma arm remain open to accrual.
Status
Open to Enrollment
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • Burkitt lymphoma
  • No prior treatment except patients may be entered if they have had prior limited-field radiotherapy, a short course of glucocorticoids and/or cyclophosphamide for an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome).
  • No prior treatment except patients may be entered if they have had prior limited-field radiotherapy, a short course of glucocorticoids and/or cyclophosphamide for an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome).
  • All disease stages.
  • ECOG 0-4
  • No active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year. If echo is obtained the LVEF should exceed 40%.
  • No HIV positive patients with advanced immune supression and evidence of HIV resistant to all combinations of antiretroviral therapy considered at high risk of non lymphoma related death within 12-months due to other AIDS complications should not be enrolled on the study.
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org